INTRODUCTION
Age-related macular degeneration (AMD) is the leading cause of irreversible visual loss in patients older than 50 years in developed countries. 1 There are currently three available drugs for the treatment of neovascular AMD: off-label use of bevacizumab (Avastin; Genentech, South San Francisco, CA), on-label use of ranibizumab (Lucentis; Genentech, South San Francisco, CA), and aflibercept (Eylea; Regeneron, Tarrytown, NY). Results from randomized clinical trials (RCTs) have demonstrated the efficacy of anti-vascular endothelial growth factor (VEGF) agents in improving vision and preventing visual loss. In the CATT study, patients treated in a fixed monthly dosing regimen with either ranibizumab or bevacizumab gained, on average, 8.2 letters, and patients treated in an as-needed regimen gained 6.4 letters after 1 year of treatment. 2 Despite the visual gains achieved, 19% to 22% of patients lost less than four letters, 6.7% of patients lost five to 14 letters, and 5.8% of patients lost more than 15 letters after receiving monthly anti-VEGF therapy. 2 However, in clinical practice, many physicians switch anti-VEGF treatments when patients do not show adequate anatomic and/or visual improvements. In fact, a 2016 Preferences and Trends survey for the American Society of Retinal Specialists found that 77% of those surveyed would switch to an alternative anti-VEGF drug in non-responding cases after three to six injections, 12% would switch after fewer than three injections, and 12.5% would switch after more than six injections. Inter-estingly, although 59% of U.S. retina specialists believed in the efficacy of switching therapies, the remaining 41% were either not sure about this benefit or preferred to not switch drugs.
One of the major issues with regard to switching anti-VEGF drugs is the lack of adequate controlled studies comparing between patients who were treated with a single drug and those treated with different drugs. In addition, there are no studies comparing between switching therapies early in the course of treatment versus switching therapies in a more chronic stage of the disease. The current review looks specifically at the timing of switching in various studies and whether this had an effect on treatment outcomes.
PATIENTS AND METHODS
The search strategy included searches in Medline, PubMed, and Embase and included the search items "age-related macular degeneration," "neovascular AMD," "aflibercept," "ranibizumab," "bevacizumab," "anti-VEGF," "switch," "conversion," "change," "refractory," "recalcitrant," "nonresponders." and "resistant." This review only included all published literature prior to August 2016 and studies that switched patients who were refractory to previous anti-VEGF therapy, had a clear definition of refractoriness or nonresponse, had an adequate number of patients (> 10 patients), had an adequate follow-up duration (> 3 months), and were published in English. A total of 38 studies met these criteria.
The exact definition of switching early or late in the course of treatment has not been previously defined for AMD. The post hoc analysis of several RCTs had identified a group of delayed responders (13% to 15%), with a peak response at 12 months after therapy initiation and further stabilization in the following 24 months of the study. 3, 4 Therefore, for the purpose of this review, early switching was defined as patients who received less than 12 injections in the course of treatment compared to chronic patients who received more than 12 injections. This cut-off point was chosen to separate the effect of a delayed response of treatment in general from the effect of switching to a new anti-VEGF.
RESULTS

Studies on Switching Anti-VEGF Therapies After Less Than 12 Injections
Switching to Ranibizumab: A total of three studies looked at the effects of switching to ranibizumab in nonresponsive cases.
In a retrospective study, Moisseiev et al. looked at 110 patients previously treated with bevacizumab who were switched to ranibizumab. 5 Patients were switched early after receiving a mean of 9.2 injections of bevacizumab (47.3% switched after three to six injections). There was no significant improvement in visual acuity (VA) before or after three injections of ranibizumab (VA before switching: 0.50 logMAR, VA after switching: 0.52 logMAR; P = .34). There was a significant decrease in central retinal thickness (CRT) 3 months after switching (CRT before switching: 292 µm, CRT after switching: 255 µm; P = .003). On further analysis, the study found that eyes that either lost greater than 0.1 logMAR (approximately five EDTRS letters) in VA or showed increasing macular thickness in the last three injections immediately prior to being switched were more likely to respond both visually and anatomically to the change of the drug.
5 Similar anatomic improvements post-switching were demonstrated by Ehlken et al. and Kucukerdonmez et al. 6, 7 However, only patients in the study by Ehlken et al. showed visual improvement. 6 Switching to bevacizumab: Ehlken et al. and Kucukerdonmez et al. also evaluated the effects of transitioning patients from ranibizumab to bevacizumab. In both studies, none of the patients showed any significant anatomic or visual improvements after switching therapies.
6,7 Additionally, Pinheiro-Costa et al., in a retrospective study of 110 eyes, showed that patients previously treated with ranibizumab showed a significant decrease of approximately three letters 12 months after switched to bevacizumab (P < .001).
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In a retrospective study by Waizel et al., 19 patients treated with aflibercept were switched early to bevacizumab after a mean of 6.5 injections.
9 Although there was no significant change in vision (P = .84), the CRT improved from 367 µm (SD: 198 µm) to 335 µm (SD: 184 µm) (P = .0065) after a mean of 5.4 bevacizumab injections. These results should, however, be interpreted cautiously because there are no other studies looking at switching from aflibercept to another anti-VEGF.
Switching to aflibercept: A total of nine studies (three prospective and six retrospective studies) evaluated early switching to aflibercept (Table  A) . In the prospective studies by Kawashima et al., Singh et al., and Massamba et al., patients showed statistically significant decreases in CRT and intraretinal fluid after being switched to aflibercept. 17 Although the PRN group did not show any improvements in vision (P = .33), the fixed bimonthly group showed a statistically significant visual improvement of +3 ET-DRS letters after 12 months of follow up (P = .008). In addition, only 8% to 25% of patients lost five to 15 letters, with no significant difference between the PRN and fixed regimen groups. The study by Chan et al. also showed a significant improvement in VA of + 4 letters at 6 months after switching (P < .001) but did not find significant differences between patients who were switched from either ranibizumab or bevacizumab to aflibercept. 18 Overall, 30% to 40% of patients gained some VA compared to 30% to 55% of patients who showed visual stability without loss of vision. A relatively small percentage of patients (10% to 25%) lost vision after switching.
All the retrospective studies looking at switching from other anti-VEGF therapies to aflibercept showed statistically significant decreases in CRT at the end of follow up. [13] [14] [15] [16] [17] [18] In the study by Ricci et al., 58% of patients treated with PRN aflibercept and 42% of patients treated in the fixed bimonthly regimen group achieved fluid resolution. 17 In the study by Chan et al., all optical coherence tomography parameters (subretinal fluid [SRF] height, PED height, and central macular thickness) significantly improved after switching to aflibercept (P < .001). 18 Furthermore, there was no difference in the outcomes of switching to aflibercept regardless of the primary drug (bevacizumab or ranibizumab).
Studies on Switching After More Than 12 Prior Injections
The current review included 20 studies in which patients had received more than 12 previous injections prior to switching (16 retrospective and four prospective) (Table B) . These studies included only late switching to aflibercept with no studies being identified where patients were switched late to ranibizumab or bevacizumab. A prospective study by Mantel et al. compared patients who, after a mean of 21 injections of ranibizumab with inadequate response, were divided into two groups: a group who continued receiving ranibizumab and a group who was switched to aflibercept. 23 This study revealed that there was no significant difference in visual improvements between the two groups (aflibercept group: + two ETDRS letters; ranibizumab group: +0.5 ETDRS letters; P = .07).
Visual Outcomes
Anatomical Outcomes
All studies showed anatomical improvement at the end of follow-up, regardless of the type of fluid: SRF, intraretinal cysts (IRC), or PED. The study by Muftuoglu et al. demonstrated that 58% of eyes with SRF prior to switching achieved visual gains post-switching compared to 42% of eyes with IRC.
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Contrary to these findings, Aghdam et al. demonstrated that the presence of IRC pre-switching was associated with significant anatomic improvement (P = .016), whereas SRF was not associated with an adequate response post-switching (P = .25).31 In addition, most studies demonstrated a significant reduction in PED height and base width, as well as a decrease in the percentage of PED at the end of the study.
19,21,28-30 The effect of PED height reduction does not appear to be exclusive to aflibercept, but appears to occur at a much faster rate after switching to aflibercept as demonstrated by Massougnes et al. 20 The anatomic improvement occurs regardless the type of anti-VEGF that the patient was receiving prior to switching to aflibercept. In the study by Pinheiro-Costa et al., patients who were previously resistant to treatment with bevacizumab (group 1) or ranibizumab (group 2) were switched to aflibercept and had their outcomes compared. In group 1 there was a decrease of 65.3 µm (P = .051) compared to a decrease of 91 µm in group 2 (P < .001). Switching to aflibercept was also associated with a lower monthly reinjection rate (0.57 after switching vs. 0.76 before switching; P = .001). This study, however, showed no significant visual improvements in either group. 25 This is in line with previous data from Chan et al. and Messenger et al.
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Reinjection Frequency Post-Switching
With regard to reinjection frequency, several studies showed a reduction in treatment frequency with prolongation of injection intervals. 27 The retrospective study by Nagai et al. showed a reduction in average injections by 0.6 in the 6 months post-switch (P < .001).
27 Sarao et al. showed that the injection frequency post-switching was significantly reduced by 3.4 injections in the 6 months post-switching compared to the 6 months prior (1.9 vs. 5.3; P < .001) with a 13.6-week reinjection interval. 32 Furthermore, Barthelmes et al. demonstrated an increase in the interval between injections from 6 weeks to 8 weeks post-switch, with one less injection per year compared to the pre-switch year.
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DISCUSSION
Based on the review of literature, it is clear that switching, whether early or late, was associated with anatomic improvement, with resolution of both SRF and IRC. There have been two previous review articles that have looked into the effects of switching anti-VEGF drugs in the treatment of AMD. 33, 34 None stratified patients based on the timing of switching and included only studies prior to May 2015 (the present study included studies until August 2016).
The anatomic improvement was not accompanied by a statistically significant visual improvement at the end of follow-up in the majority of studies. 39 The reason for this discrepancy between VA and anatomy might be explained by the inherent pathology of resistant cases that may be associated with more damage to the photoreceptors. Another possibility is the lack of nonprotocol refractions during the studies' assessments, which negated any visual improvement. However, further scrutiny of the switch studies demonstrated that 20% to 25% of patients switched did have visual improvements, and approximately 40% to 50% showed visual stability. The studies also demonstrated that only a small percentage of patients (10% to 15%) had visual loss (Tables A and B) .
One of the challenges of the current review was to define the cut-off point for early versus late switching. The cut-off point of 12 injections might seem controversial, but it was chosen in light of data regarding delayed-responders. 2, 35 Based on data from previous post hoc analysis and from the current review, it can be suggested that patients who fail to respond may fall into one of three categories: early responders who show an increased resistance to therapy over time (tachyphylaxis), delayed responders, and those who fail to respond at all to therapy from the start (resistance). 2, 3, 35, 36 These data also highlight the importance of evaluating switching at different time points to study its effect on each patient category.
There were also some differences seen among the different anti-VEGFs agents. Switching to aflibercept was associated with a reduction in injection frequency with longer injection intervals. 26, 32 Switching to ranibizumab showed similar results, but there are much fewer studies available for analysis. [4] [5] [6] There are no studies looking at the effects of switching to ranibizumab after aflibercept use. Additionally, the current review also found that there are insufficient data to support the strategy of switching to bevacizumab as evidenced by the limited anatomic and visual benefits achieved.
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A significant drawback of reviewing data regarding switching anti-VEGF agents is that most of the available studies are retrospective or small prospective reports without control groups. Without adequately designed RCTs comparing the switched patients to a control (unswitched) group, it is difficult to ascertain whether switching itself is effective or whether patients responded because they received standardized timely therapy and/or they are simply delayed responders. More prospective studies comparing outcomes of early and late switching with clear definitions for each time point are required to help guide current treatment practice and determine the efficacy of switching anti-VEGF therapies. 12 months --53 µm at 1 year (P < .0001); -54 µm (P = .0004) at 2 years; 33% dryness at 1 year; 54% dryness at 2 years +2.8 letters at year 1 (P = .050); +2.9 letters at year 2 (P = .11)
CATT study 43 Patients eligible for switching at 6 months were Prospectively followed 
